Ms Debroux is group chief financial officer, executive board member, of Heineken N.V., the Netherlands.
Ms Debroux is member of the board of Exor N.V., the Netherlands, and
of HEC Paris Business School, France.
From 2010 to 2015 Ms Debroux held the position as group chief financial officer, executive board member, at JCDecaux SA, France. From 1996 to 2010 Ms Debroux held a number of positions at Sanofi Aventis (previously Sanofi SA), including those of chief strategic officer, chief financial officer and deputy chief financial officer.
Prior to this, Ms Debroux held positions in corporate finance at Elf Aquitaine, France, from 1993 to 1996, as an analyst in Corporate Finance for Merrill Lynch, UK, from 1992 to 1993, and as a research analyst for Putnam, Hayes & Bartlett, USA, from 1989 to 1990.
Ms Debroux was first elected to the Board of Novo Nordisk A/S in March 2019. Her term as a board member expires in March 2020.
In March 2019, the Board of Directors of Novo Nordisk A/S assessed
that Ms Debroux is regarded as an independent board member as defined
in Section 3.2.1 of the Recommendations on Corporate Governance
designated by Nasdaq Copenhagen.
Significant financial and accounting experience, extensive global
experience within the pharmaceutical industry and experience from
executive positions in major international companies.
1992: Master Degree, HEC Paris, Ecoles des Hautes Etudes Commerciales, France.
Ms Debroux is a French national, born July 1969.